Short hairpin RNA-mediated gene silencing
- PMID: 23027054
- DOI: 10.1007/978-1-62703-119-6_12
Short hairpin RNA-mediated gene silencing
Abstract
Since the first application of RNA interference (RNAi) in mammalian cells, the expression of short hairpin RNAs (shRNAs) for targeted gene silencing has become a benchmark technology. Using plasmid and viral vectoring systems, the transcription of shRNA precursors that are effectively processed by the RNAi pathway can lead to potent gene knockdown. The past decade has seen continual advancement and improvement to the various strategies that can be used for shRNA delivery, and the use of shRNAs for clinical applications is well underway. Driving these developments has been the many benefits afforded by shRNA technologies, including the stable integration of expression constructs for long-term expression, infection of difficult-to-target cell lines and tissues using viral vectors, and the temporal control of shRNA transcription by inducible promoters. The use of different effector molecule formats, promoters, and vector types, has meant that experiments can be tailored to target specific cell types and minimize cellular toxicities. Through the application of combinatorial RNAi (co-RNAi), multiple shRNA delivery strategies can improve gene knockdown, permit multiple transcripts to be targeted simultaneously, and curtail the emergence of viral escape mutants. This chapter reviews the history, cellular processing, and various applications of shRNAs in mammalian systems, including options for effector molecule design, vector and promoter types, and methods for multiple shRNA delivery.
Similar articles
-
Construction of simple and efficient DNA vector-based short hairpin RNA expression systems for specific gene silencing in mammalian cells.Methods Mol Biol. 2007;408:223-41. doi: 10.1007/978-1-59745-547-3_13. Methods Mol Biol. 2007. PMID: 18314586
-
Effective knockdown of multiple target genes by expressing the single transcript harbouring multi-cistronic shRNAs.Biochem Biophys Res Commun. 2010 Jun 11;396(4):861-5. doi: 10.1016/j.bbrc.2010.05.008. Epub 2010 May 6. Biochem Biophys Res Commun. 2010. PMID: 20451494
-
Expressing functional siRNAs in mammalian cells using convergent transcription.BMC Biotechnol. 2003 Nov 6;3:21. doi: 10.1186/1472-6750-3-21. BMC Biotechnol. 2003. PMID: 14604435 Free PMC article.
-
Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.Adv Drug Deliv Rev. 2009 Jul 25;61(9):760-6. doi: 10.1016/j.addr.2009.04.006. Epub 2009 Apr 20. Adv Drug Deliv Rev. 2009. PMID: 19386274 Review.
-
Approaches for chemically synthesized siRNA and vector-mediated RNAi.FEBS Lett. 2005 Oct 31;579(26):5974-81. doi: 10.1016/j.febslet.2005.08.070. Epub 2005 Sep 20. FEBS Lett. 2005. PMID: 16199038 Review.
Cited by
-
TALEN-mediated somatic mutagenesis in murine models of cancer.Cancer Res. 2014 Sep 15;74(18):5311-21. doi: 10.1158/0008-5472.CAN-14-0529. Epub 2014 Jul 28. Cancer Res. 2014. PMID: 25070752 Free PMC article.
-
Nanoparticulate RNA delivery systems in cancer.Cancer Rep (Hoboken). 2020 Oct;3(5):e1271. doi: 10.1002/cnr2.1271. Epub 2020 Jul 30. Cancer Rep (Hoboken). 2020. PMID: 32729987 Free PMC article. Review.
-
Drug delivery approaches for HuR-targeted therapy for lung cancer.Adv Drug Deliv Rev. 2022 Jan;180:114068. doi: 10.1016/j.addr.2021.114068. Epub 2021 Nov 22. Adv Drug Deliv Rev. 2022. PMID: 34822926 Free PMC article. Review.
-
Systemic RNAi delivery to the muscles of ROSA26 mice reduces lacZ expression.PLoS One. 2014 Aug 15;9(8):e102053. doi: 10.1371/journal.pone.0102053. eCollection 2014. PLoS One. 2014. PMID: 25127128 Free PMC article.
-
Gene therapy to enhance angiogenesis in chronic wounds.Mol Ther Nucleic Acids. 2022 Aug 17;29:871-899. doi: 10.1016/j.omtn.2022.08.020. eCollection 2022 Sep 13. Mol Ther Nucleic Acids. 2022. PMID: 36159590 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
